Natera, Inc. $NTRA is Beaconlight Capital LLC’s 9th Largest Position

Beaconlight Capital LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 44.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 33,589 shares of the medical research company’s stock after acquiring an additional 10,303 shares during the quarter. Natera comprises 3.6% of Beaconlight Capital LLC’s investment portfolio, making the stock its 9th largest holding. Beaconlight Capital LLC’s holdings in Natera were worth $6,717,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Robinhood Asset Management LLC bought a new stake in Natera during the fourth quarter valued at approximately $12,981,000. J. Safra Sarasin Holding AG purchased a new stake in shares of Natera during the 4th quarter valued at $2,825,000. UBS Group AG lifted its holdings in shares of Natera by 19.4% during the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after acquiring an additional 71,355 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Natera by 25.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 45,835 shares of the medical research company’s stock worth $11,476,000 after acquiring an additional 9,424 shares in the last quarter. Finally, Dakota Wealth Management bought a new position in Natera in the fourth quarter valued at $1,356,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NTRA stock opened at $261.99 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The company has a market capitalization of $37.52 billion, a price-to-earnings ratio of -160.73 and a beta of 1.51. The business’s 50 day moving average price is $240.75 and its two-hundred day moving average price is $221.61.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Wells Fargo & Company upped their target price on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. The Goldman Sachs Group initiated coverage on shares of Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Finally, William Blair initiated coverage on shares of Natera in a report on Tuesday, April 14th. They set an “outperform” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Insider Buying and Selling

In other Natera news, Director Rowan E. Chapman sold 2,964 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the completion of the transaction, the director owned 3,124 shares of the company’s stock, valued at approximately $677,220.72. This trade represents a 48.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,872 shares of company stock valued at $39,627,696 over the last 90 days. 5.05% of the stock is currently owned by company insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.